Urgent.News

What's breaking now, across thousands of outlets.

More in Finance & Markets

GSK: 3 Key Takeaways for Long-Term Investors

Cost discipline is offsetting R&D investment without squeezing margins, the financial foundation for sustained portfolio transformation.

  • GSK reaffirmed full-year 2026 guidance, with sales growing 5% to £8.9 billion
  • Accelerated R&D pipeline initiated 18 phase 3 clinical trials in 2026, aiming for 22 by year-end

More from Tuesday 17 November →